Selective estrogen receptor degrader AND019
Term · Oncology and biomedicine · MLC-T-ONC-016668
An orally bioavailable selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD AND019 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
| Identifier | MLC-T-ONC-016668 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | SERD AND019 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016668",
"term": "Selective estrogen receptor degrader AND019",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD AND019 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.",
"synonyms": [
"SERD AND019"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/selective-estrogen-receptor-degrader-and019/"
}
Record 14,796 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.